The p22-phox subunit is an essential component of NAD(P)H oxidase enzymatic complex, which is considered the major source of oxidative stress products in the cardiovascular system.
1,2
The À930G allele of p22-phox has been associated with higher promoter activity, increased NAD(P)H oxidase-mediated oxidative stress and hypertension.
3,4
We recently reported that left ventricular hypertrophy is accompanied by increased myocardial p22-phox expression in aortic-banded rats, suggesting that this protein might be involved in hypertensive cardiac hypertrophy.
2 Thus, the aim of the present report was to investigate the role of p22-phox À930A/G polymorphism on end-organ damage in hypertensive patients.
The study was carried out in 194 hypertensive patients followed up at the Hypertension Unit of State University of Campinas and in 70 normotensive volunteers recruited between January 2005 and December 2006. Clinical data were based on medical history, physical examination and routine analytical tests. Echocardiographic evaluation was performed as previously described. 5 Genomic DNA was extracted from peripheral blood leucocytes, amplified by polymerase chain reaction and polymorphisms were detected by restriction reaction. 3 The study was approved by the Ethics Committee of the State University of Campinas, and informed consent was obtained from all participants. Data are expressed as means7s.e. The statistical significance of differences was analysed by Student's t-test. Comparisons between categoric variables were made by w 2 test. 3, 6 In order to enhance statistical power and given the described functional effect of GG in comparison to AA and AG genotypes, 3, 4 AA subjects were added to AG ones. There were no differences regarding gender, age, diabetes mellitus, smoking, blood pressure, body mass index, abdominal circumference, metabolic profile, C-reactive protein as well as markers of renal damage and echocardiographic parameters between the genotype groups (AA/AG and GG) in hypertensive subjects. After adjusting the analyses by age, sex and body mass index, no significant differences were further detected. Ninety-four per cent of patients were taking antihypertensive medications, while 26 and 1% were using statins and fibrates, respectively. Nevertheless, we found no statistical differences in the frequency of these medications and in the dosage of antihypertensives between the genotypic subgroups, except for an unparalleled use of atenolol in five patients of the AA/AG group (Table 1) . Moreover, genotype groups (AA/AG and GG) of normotensive subjects presented similar clinical, metabolic, renal and echocardiographic features, strengthening the idea that the À930A/G polymorphism plays no major role in these parameters.
Previous observations demonstrated that p22-phox À930GG genotype is associated with increased leukocyte-derived superoxide production in hypertensives but not in normotensives, 4 indicating that individuals harbouring this genotype could be exposed to higher oxidative stress under conditions of pressure overload. Since oxidative stress is implicated in the pathogenesis of hypertensive end-organ damage 1,2 and p22-phox is expressed in human vascular, cardiac and renal tissues, 1,7,8 we investigated here whether this putative prooxidant variant might affect cardiac and renal injury mediated by hypertension. In contrast to our hypothesis, the present results showed that the p22-phox À930A/G polymorphism does not affect left ventricular mass or geometric pattern and renal function or albuminuria in hypertensive patients. However, genetic variants involved in oxidative stress pathways may still play a substantial part in the determination of the deleterious effects of hypertension, regardless of the failure of the present study to show a significant role for the À930A/G polymorphism. In this context, mutation scanning of more candidate genes in the NAD(P)H-oxidase system is likely to expand our knowledge of the role of genetic factors in hypertensive end-organ damage.
Previous data obtained in Spanish and Japanese samples showed a positive association between the GG genotype and hypertension. 3, 6 In the present report, we did not confirm this presumed association in a sample of Brazilian subjects, suggesting that the À930A/G variant of p22-phox might not confer susceptibility to hypertension. Nevertheless, further studies in larger populations are required to elucidate this issue.
Our study has some potential limitations. Although the frequency of medications and average dosages of antihypertensives were mostly similar between the genotype groups, we cannot exclude the possibility that the use of medications could have influenced our results. Next, our sample size was limited. Even though statistical power of Left Ventricular Mass Index and log-transformed urinary albumin/creatinine ratio was beyond 50%, a large number of 784 hypertensives should have been enrolled to achieve a sufficient power for all studied parameters. In this context, the possibility of a type 2 error cannot be ruled out in our investigation.
In conclusion, our results provide no support to the hypothesis that p22-phox À930A/G polymorphism is involved in cardiac/renal injury induced by hypertension. Further studies are necessary to evaluate whether genetic variants involved in oxidative stress pathways play a role in hypertensive end-organ damage. 
